HMNC Pushes On With Biomarker-Driven Depression Drug After Setback

Company Refines Genetic Tool, Eyes Phase III Despite Phase II Miss

 
• By Sushmita Panda
  
Hans Eriksson, chief medical officer at HMNC Brain Health
Photograph of Hans Eriksson, chief medical officer at HMNC Brain Health

More from Clinical Trials

More from R&D